OLD Category: immuno-oncology

Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment

• Qiao G, Chen M, Mohammadpour H, MacDonald CR, Bucsek MJ, Hylander BL, Barbi JJ, Repasky EA

MYC oncogene is associated with suppression of tumor immunity and targeting Myc induces tumor cell immunogenicity for therapeutic whole cell vaccination

• Wu X, Nelson M, Basu M, Srinivasan P, Lazarski C, Zhang P, Zheng P, Sandler AD

Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models

• Wang J, Hu Y, Escamilla-Rivera V, Gonzalez CL, Tang L, Wang B, El-Naggar AK, Myers JN, Caulin C

PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

• Pinato DJ, Cortellini A, Sukumaran A...Yip V, Slater S, Sharma R

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

• Griguolo G, Serna G, Pascual T...Villagrasa P, Prat A, Nuciforo P

Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors

• Rosewell Shaw A, Porter CE, Yip T, Mah WC, McKenna MK, Dysthe M, Jung Y, Parihar R, Brenner MK, Suzuki M

Cross-platform comparison of immune-related gene expression to assess intratumor immune responses following cancer immunotherapy

• Zhang L, Cham J, Cooley J...Thompson D, Kerns BJ, Fong L

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

• Gandhi MK, Hoang T, Law SC...Bojarczuk K, Chapuy B, Keane C

Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer

• Quintana A, Peg V, Prat A...Vazquez M, De Mattos-Arruda L, Cortes J

Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti–PD-1 Refractory Melanoma

• Haymaker C, Johnson DH, Murthy R...Markowitz J, Bernatchez C, Diab A

Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile

• Younis RH, Ghita I, Elnaggar M...Webb TJ, Bentzen SM, Lubek JE

Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial

• Lim J, Park Y, Ahn JW...Sung KS, Kwack K, Cho K